<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[sandoz Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/sandoz.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to sandoz]]></description>
	<s:counts start="0" returned="20" found="39" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Sanofi, Sandoz among firms in antitrust raid]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/sanofi-sandoz-firms-antitrust-raid/14872/]]></link>
		<description><![CDATA[As we went to press yesterday, word was just emerging about the European Commission's round of raids on pharma companies. Today, we have some news about just which drugmakers got surprise visits from antitrust watchdogs. According to press reports and company statements, regulators visited Sanofi-Aventis, Teva Pharmaceutical Industries, the Novartis...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 08 Oct 2009 02:13:45 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/antitrust.html"><![CDATA[Antitrust]]></category>
	</item>
	<item>
		<title><![CDATA[Medicis' Solodyn Sales Stay Strong Despite Generic Challenges; Pay-to-Delay Works]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004494/medicis-solodyn-sales-stay-strong-despite-generic-challenges-pay-to-delay-works/]]></link>
		<description><![CDATA[Despite both Teva and Sandoz dipping their generic toes into the Solodyn acne franchise, sales of Medicis' pimple-popper are still going up. Why? Because Medicis has paid most of those rivals to stop making their versions of the drug. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 29 Sep 2009 08:20:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/medicis.html"><![CDATA[Medicis]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[More generics receive clearance for marketing by the FDA]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb3007/is_21_30/ai_n31196470]]></link>
		<description><![CDATA[WASHINGTON -- The Actavis Group has received Food and Drug Administration approval to market bupropion hydrochloride extended-release tablets, 150 mg. The company also markets a 300-mg version of the product, indicated for the treatment of major depressive disorder.  Annual sales of brand and generic versions of the drug in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 08 Dec 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+pharmaceuticals+inc..html"><![CDATA[Mylan Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[&#39;Father of LSD&#39; takes final trip]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200804/ai_n25366647]]></link>
		<description><![CDATA[GENEVA AFP &#8212; Albert Hofmann, the Swiss chemist who discovered the now-banned hallucinogenic drug LSD that was an icon of the Hippy movement, has died at the age of 102, authorities said Wednesday.  The scientist, born in Baden in northern Switzerland in 1906, worked for chemicals company Sandoz from...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 30 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/engineering.html"><![CDATA[Engineering]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/scientist.html"><![CDATA[scientist]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Generics Giant Sandoz Completes $10 Million Expansion in North Carolina, an Industrial Info News Alert]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200712/ai_n21177599]]></link>
		<description><![CDATA[Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Dovetailing nicely with the continuing demand for generic drug products, Sandoz has completed a $10 million expansion at its Wilson, North Carolina, Center of Excellence site. The project added 30,000 square feet to the 170,000-square-foot facility. Sandoz is the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 28 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Research & Markets: With Sales of Over US$4.6 Billion Sandoz is Currently the Second Largest Generic Manufacturer in the World]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_May_30/ai_n27256367]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 30 May 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[sales]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Savient Pharmaceuticals Announces Appellate Court Decision in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_12/ai_n27083381]]></link>
		<description><![CDATA[US Court of Appeals for the Federal Circuit Temporarily Enjoins Launch of Generic Oxandrolone]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 12 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Savient Pharmaceuticals Announces Modification of Temporary Restraining Order in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_11/ai_n16884104]]></link>
		<description><![CDATA[EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the U.S. District Court for the District of New Jersey, after considering legal briefs and supporting affidavits from all parties, ordered late on Friday that the temporary restraints contained in the Temporary Restraining Order ("TRO") previously issued by...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 11 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Savient Pharmaceuticals Files Patent Infringement Lawsuit Against Sandoz Pharmaceuticals and Upsher-Smith Laboratories]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_4/ai_n16881387]]></link>
		<description><![CDATA[Announces Distribution Agreement with Watson Pharmaceuticals for Authorized Generic of Oxandrin([R])]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 04 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Research & Markets: The Sandoz Generics Division is Still the Principal Driver of Growth for Novartis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_7/ai_n27032394]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44741) has announced the addition of Corporate Focus Healthcare: Novartis Q3 2006 to their offering.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 07 Nov 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Sanofi fighting generic drugs tooth and nail in US courts]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200608/ai_n16612116]]></link>
		<description><![CDATA[PARIS AFP &#8212; The French pharmaceuticals group Sanofi-Aventis is turning to vigorous legal action to protect its best-selling drugs in the United States from cheaper generic competition.  "We are sure of our patents," a spokesman for Sanofi-Aventis, the world's third largest drug group, said Wednesday.  Sanofi announced it...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 09 Aug 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi.html"><![CDATA[Sanofi]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi-aventis.html"><![CDATA[Sanofi-Aventis]]></category>
		<category domain="http://resources.bnet.com/topic/spokesman.html"><![CDATA[spokesman]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Wilson.(EASTERN)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6617/is_200607/ai_n26056286]]></link>
		<description><![CDATA[WILSON -- Sandoz, part of Swiss drug maker Novartis, plans to spend  $10 million to expand research and development and add 65 jobs here  within ...  WILSON -- Sandoz, part of Swiss drug maker Novartis, plans to spend  $10 million to expand research and development and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 01 Jul 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[job]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor®]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_June_23/ai_n26905658]]></link>
		<description><![CDATA[JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Novartis' generic unit, Sandoz, Inc., has filed a complaint in the United States District Court for the District of Columbia, seeking approval of its generic ZocorR products in the face of an April 30, 2006 decision of the same...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 23 Jun 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Sandoz gets precedent-setting US approval for Omnitrope(R) as first follow-on version of a previously approved recombinant biotechnology drug]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200605/ai_n16430301]]></link>
		<description><![CDATA[--  US approval a breakthrough in goal of making high-quality and cost-     effective follow-on biotechnology medicines available for patients  --  Omnitrope now approved for treatment of growth disorders in children     and adults in the US, the European Union and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 31 May 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Research and Markets: Gain an Understanding of the Complex Issues Affecting Sandoz the Generics Company]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_April_26/ai_n26840170]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 26 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[340B Prime Vendor Program Adds Sandoz Pharmaceuticals to Growing List of Companies Providing Low-Income Americans With Access to Antibiotic Injectibles and Oral Solid Medications]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200604/ai_n16122135]]></link>
		<description><![CDATA[The 340B Prime Vendor Program, managed by HealthCare Purchasing Partners International® HPPI announced today that it has added global pharmaceutical leader Sandoz a division of Novartis to its growing list of companies providing drugs, supplies and medical devices to clinics, hospitals and health care programs for low-income Americans. HPPI's three-year...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 10 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/microsoft+access.html"><![CDATA[Microsoft Access]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Unigene and Novartis Complete Technology Transfer For Calcitonin Manufacturing; Sandoz Successfully Concludes First Full-Scale Production Campaign]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_August_22/ai_n14929107]]></link>
		<description><![CDATA[FAIRFIELD, N.J. -- The transfer of Unigene Laboratories, Inc. (OTCBB: UGNE) proprietary manufacturing technology to Novartis for manufacturing calcitonin has been completed successfully.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 22 Aug 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Research and Markets: Novartis and Sandoz Eyeing the Lucrative Erythropoietin Market]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_July_29/ai_n14837036]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c21659) has announced the addition of Erythropoietin Current Market Dynamics & Future Outlook to their offering.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 29 Jul 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Think what's possible.(pharmaceutical industry)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb3396/is_200503/ai_n15082019]]></link>
		<description><![CDATA[Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and  consumer health. In 2003, the Group's businesses achieved sales of  $24.9 billion and a net income of $5.0 billion. The Group invested  approximately $3.8 billion in Research & Development. Headquartered  in Based, Switzerland, Novartis Group...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Mar 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/ciba+vision+corp..html"><![CDATA[CIBA Vision Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Frost & Sullivan Award Recognises Sandoz's Competitive Strategy Leadership in Global Biopharmaceutical Market.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200502/ai_n24130310]]></link>
		<description><![CDATA[LONDON, February 16 /PRNewswire/ --     The 2004 Frost &  Sullivan Competitive Strategy Leadership Award is presented to Sandoz  for its clear demonstration of gains in market share through development  of innovative and high-quality solutions for the overall growth of the  biopharmaceuticals industry....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 16 Feb 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/frost+%2526+sullivan.html"><![CDATA[Frost & Sullivan]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/sandoz.html"><![CDATA[Sandoz]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
